Abstract
The mechanistic/mammalian target of rapamycin (mTOR) is the crucial hub of signalling pathways that regulate essential steps in the cell life cycle. Once incorporated in the mTORC1 complex, mTOR phosphorylates the eukaryotic initiation factor 4E (eIF4E)- binding protein 1 (4E-BP1), which then releases eIF4E. When not bound to 4EBPs, eIF4E recognizes the mRNA 5’-cap structure and, together with eIF4A and eIF4G, it forms the eIF4F complex that recruits the ribosome on the mRNA. Under normal conditions, the cellular concentration of eIF4E is very low, making eIF4E the limiting factor in the initiation of protein synthesis. The vast majority of cancer types are characterized by the simultaneous deregulation of the mTOR/4E-BP1 signalling pathway and upregulation of eIF4E, which lead to an increased expression of cancer-promoting genes and deregulated cellular growth. Over the last decades, a growing number of selective inhibitors of the mTOR/4E-BP1/eIF4E pathway have been discovered or designed. Several inhibitors with encouraging preclinical results have been tested in clinical trials. This review summarizes the most recent research on drug development against mTOR, 4E-BP1, and eIF4E, describing the design rationale and the available structural and functional data on the most promising compounds.
Keywords: mTOR allosteric inhibitors, rapamycin, eIF4F, translational control, cancer, PIKKs.
Current Medicinal Chemistry
Title:The mTOR/4E-BP1/eIF4E Signalling Pathway as a Source of Cancer Drug Targets
Volume: 29 Issue: 20
Author(s): Cristina Maracci, Stefano Motta, Alice Romagnoli, Matteo Costantino, Paola Perego*Daniele Di Marino
Affiliation:
- Molecular Pharmacology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Keywords: mTOR allosteric inhibitors, rapamycin, eIF4F, translational control, cancer, PIKKs.
Abstract: The mechanistic/mammalian target of rapamycin (mTOR) is the crucial hub of signalling pathways that regulate essential steps in the cell life cycle. Once incorporated in the mTORC1 complex, mTOR phosphorylates the eukaryotic initiation factor 4E (eIF4E)- binding protein 1 (4E-BP1), which then releases eIF4E. When not bound to 4EBPs, eIF4E recognizes the mRNA 5’-cap structure and, together with eIF4A and eIF4G, it forms the eIF4F complex that recruits the ribosome on the mRNA. Under normal conditions, the cellular concentration of eIF4E is very low, making eIF4E the limiting factor in the initiation of protein synthesis. The vast majority of cancer types are characterized by the simultaneous deregulation of the mTOR/4E-BP1 signalling pathway and upregulation of eIF4E, which lead to an increased expression of cancer-promoting genes and deregulated cellular growth. Over the last decades, a growing number of selective inhibitors of the mTOR/4E-BP1/eIF4E pathway have been discovered or designed. Several inhibitors with encouraging preclinical results have been tested in clinical trials. This review summarizes the most recent research on drug development against mTOR, 4E-BP1, and eIF4E, describing the design rationale and the available structural and functional data on the most promising compounds.
Export Options
About this article
Cite this article as:
Maracci Cristina, Motta Stefano, Romagnoli Alice, Costantino Matteo, Perego Paola*, Di Marino Daniele, The mTOR/4E-BP1/eIF4E Signalling Pathway as a Source of Cancer Drug Targets, Current Medicinal Chemistry 2022; 29 (20) . https://dx.doi.org/10.2174/0929867329666220224112042
DOI https://dx.doi.org/10.2174/0929867329666220224112042 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aptamer-Targeted Oligonucleotide Theranostics: A Smarter Approach for Brain Delivery and the Treatment of Neurological Diseases
Current Topics in Medicinal Chemistry Stress Related Neuroendocrine Influences in Ovarian Cancer
Current Cancer Therapy Reviews Design, Synthesis and Biological Evaluation of New 1,3-diphenyl-3- (phenylamino)propan-1-ones as Selective Cyclooxygenase (COX-2) Inhibitors
Medicinal Chemistry Model Membrane and Cell Studies of Antimicrobial Activity of Melittin Analogues
Current Topics in Medicinal Chemistry Recent Advances in the Syntheses of Nucleoside Triphosphates
Current Organic Synthesis Gedunin, A Neem Limonoid in Combination with Epalrestat Inhibits Cancer Hallmarks by Attenuating Aldose Reductase-Driven Oncogenic Signaling in SCC131 Oral Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Real-time Protein Monitoring Based on Molecular Beacons
Current Proteomics Microbial Interactions in Plants: Perspectives and Applications of Proteomics
Current Protein & Peptide Science Artificial Intelligence, Big Data and Machine Learning Approaches in Precision Medicine & Drug Discovery
Current Drug Targets Synthesis and Antitumor Activity of Novel 4-Chloro-3-Arylmaleimide Derivatives
Letters in Drug Design & Discovery Evaluation of Drug Transporter Interactions in Drug Discovery and Development
Combinatorial Chemistry & High Throughput Screening Angiotensin Peptides as AT2 Receptor Agonists
Current Protein & Peptide Science HPV and Therapeutic Vaccines: Where are We in 2010?
Current Cancer Therapy Reviews Preliminary Study on the Mechanism of Carvacrol Regulating Hepatocellular Carcinoma Based on Network Pharmacology
Letters in Drug Design & Discovery Dapsone-Loaded Microsponge Gel for Acne Management: Preparation, Characterization and Anti-Microbial Activity
Micro and Nanosystems Important Aspects of Post-Prandial Antidiabetic Drug, Acarbose
Current Topics in Medicinal Chemistry Use of Nanosilver in Consumer Products
Recent Patents on Nanotechnology N-Substituted-2-butyl-5-chloro-3H-imidazole-4-carbaldehyde Derivatives as Anti-tumor Agents Against Ehrlich Ascites tumor Cells In Vivo
Medicinal Chemistry Determination of Residual Solvents in Eprosartan Mesylate by Static Headspace Gas Chromatographic Method Optimized by Response Surface Methodology
Current Pharmaceutical Analysis iHyd-PseAAC (EPSV): Identifying Hydroxylation Sites in Proteins by Extracting Enhanced Position and Sequence Variant Feature via Chou's 5- Step Rule and General Pseudo Amino Acid Composition
Current Genomics